BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mevorach D, Reiner I, Grau A, Ilan U, Berkun Y, Ta-shma A, Elpeleg O, Shorer Z, Edvardson S, Tabib A. Therapy with eculizumab for patients with CD59 p.Cys89Tyr mutation: Eculizumab for Non-Functional CD59. Ann Neurol 2016;80:708-17. [DOI: 10.1002/ana.24770] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Chai JN, Azad AK, Kuan K, Guo X, Wang Y. A Splice Site Mutation Associated with Congenital CD59 Deficiency. Hematology Reports 2022;14:172-8. [DOI: 10.3390/hematolrep14020025] [Reference Citation Analysis]
2 McCombe JA, Pittock SJ. Anti-complement Agents for Autoimmune Neurological Disease. Neurotherapeutics 2022. [PMID: 35553024 DOI: 10.1007/s13311-022-01223-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Latov N. Immune mechanisms, the role of complement, and related therapies in autoimmune neuropathies. Expert Rev Clin Immunol 2021;17:1269-81. [PMID: 34751638 DOI: 10.1080/1744666X.2021.2002147] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Pignataro G, Cataldi M, Taglialatela M. Neurological risks and benefits of cytokine-based treatments in coronavirus disease 2019: from preclinical to clinical evidence. Br J Pharmacol 2021. [PMID: 33512003 DOI: 10.1111/bph.15397] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Dalakas MC, Alexopoulos H, Spaeth PJ. Complement in neurological disorders and emerging complement-targeted therapeutics. Nat Rev Neurol 2020;16:601-17. [PMID: 33005040 DOI: 10.1038/s41582-020-0400-0] [Cited by in Crossref: 70] [Cited by in F6Publishing: 76] [Article Influence: 35.0] [Reference Citation Analysis]
6 Roy B, Nowak RJ. Eculizumab in Acute Motor Axonal Neuropathy: An Ethical Application of an Off-Label Indication. J Clin Neuromuscul Dis 2020;22:63-4. [PMID: 32833730 DOI: 10.1097/CND.0000000000000295] [Reference Citation Analysis]
7 Wijnsma KL, Ter Heine R, Moes DJAR, Langemeijer S, Schols SEM, Volokhina EB, van den Heuvel LP, Wetzels JFM, van de Kar NCAJ, Brüggemann RJ. Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab. Clin Pharmacokinet 2019;58:859-74. [PMID: 30758736 DOI: 10.1007/s40262-019-00742-8] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 29.5] [Reference Citation Analysis]
8 Kurolap A, Eshach Adiv O, Hershkovitz T, Tabib A, Karbian N, Paperna T, Mory A, Vachyan A, Slijper N, Steinberg R, Zohar Y, Mevorach D, Baris Feldman H. Eculizumab Is Safe and Effective as a Long-term Treatment for Protein-losing Enteropathy Due to CD55 Deficiency. J Pediatr Gastroenterol Nutr 2019;68:325-33. [PMID: 30418410 DOI: 10.1097/MPG.0000000000002198] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
9 Di Stefano V, Barbone F, Ferrante C, Telese R, Vitale M, Onofrj M, Di Muzio A. Inflammatory polyradiculoneuropathies: Clinical and immunological aspects, current therapies, and future perspectives. Eur J Inflamm 2020;18:205873922094234. [DOI: 10.1177/2058739220942340] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
10 Pode-shakked B, Heimer G, Vilboux T, Marek-yagel D, Ben-zeev B, Davids M, Ferreira CR, Philosoph AM, Veber A, Pode-shakked N, Kenet G, Soudack M, Hoffmann C, Vernitsky H, Safaniev M, Lodzki M, Lahad A, Shouval DS, Levinkopf D, Weiss B, Barg AA, Daka A, Amariglio N, Malicdan MCV, Gahl WA, Anikster Y. Cerebral and portal vein thrombosis, macrocephaly and atypical absence seizures in Glycosylphosphatidyl inositol deficiency due to a PIGM promoter mutation. Molecular Genetics and Metabolism 2019;128:151-61. [DOI: 10.1016/j.ymgme.2019.08.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
11 Schröder-Braunstein J, Kirschfink M. Complement deficiencies and dysregulation: Pathophysiological consequences, modern analysis, and clinical management. Mol Immunol 2019;114:299-311. [PMID: 31421540 DOI: 10.1016/j.molimm.2019.08.002] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 12.0] [Reference Citation Analysis]
12 Ye Z, Huang Y, Wang Y, Lu J, Wu J, Yu Z. Phenotype and Genotype of a Cohort of Chinese Children with Early-Onset Protein-Losing Enteropathy. J Pediatr 2019;208:38-42.e3. [PMID: 30853196 DOI: 10.1016/j.jpeds.2018.12.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
13 Duchateau L, Martín-Aguilar L, Lleixà C, Cortese A, Dols-Icardo O, Cervera-Carles L, Pascual-Goñi E, Diaz-Manera J, Calegari I, Franciotta D, Rojas-Garcia R, Illa I, Clarimon J, Querol L. Absence of pathogenic mutations in CD59 in chronic inflammatory demyelinating polyradiculoneuropathy. PLoS One 2019;14:e0212647. [PMID: 30794663 DOI: 10.1371/journal.pone.0212647] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
14 Keller CW, Quast I, Dalakas MC, Lünemann JD. IVIG efficacy in CIDP patients is not associated with terminal complement inhibition. J Neuroimmunol 2019;330:23-7. [PMID: 30772754 DOI: 10.1016/j.jneuroim.2019.02.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
15 Yuksel D, Oguz KK, Azapagası E, Kesici S, Cavdarli B, Konuskan B, Topaloglu H. Uncontrolled inflammation of the nervous system: Inherited CD59 deficiency. Neurol Clin Pract 2018;8:e18-20. [PMID: 30564502 DOI: 10.1212/CPJ.0000000000000511] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
16 Duchateau L, Martin-aguilar L, Lleixà C, Cortese A, Dols-icardo O, Cervera-carles L, Pascual-goñi E, Diaz-manera J, Calegari I, Franciotta D, Rojas-garcia R, Illa I, Clarimon J, Querol L. Absence of pathogenic mutations in CD59 in chronic inflammatory demyelinating polyradiculoneuropathy.. [DOI: 10.1101/459917] [Reference Citation Analysis]
17 Sommer C. S2e-Leitlinie: Therapie akuter und chronischer immunvermittelter Neuropathien und Neuritiden: Leitlinie der Deutschen Gesellschaft für Neurologie. DGNeurologie 2018;1:89-103. [DOI: 10.1007/s42451-018-0022-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
18 Karbian N, Eshed-Eisenbach Y, Tabib A, Hoizman H, Morgan BP, Schueler-Furman O, Peles E, Mevorach D. Molecular pathogenesis of human CD59 deficiency. Neurol Genet 2018;4:e280. [PMID: 30533526 DOI: 10.1212/NXG.0000000000000280] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
19 Kieseier BC, Mathey EK, Sommer C, Hartung H. Immune-mediated neuropathies. Nat Rev Dis Primers 2018;4. [DOI: 10.1038/s41572-018-0027-2] [Cited by in Crossref: 52] [Cited by in F6Publishing: 55] [Article Influence: 13.0] [Reference Citation Analysis]
20 Kawamoto M, Murakami Y, Kinoshita T, Kohara N. Recurrent aseptic meningitis with PIGT mutations: a novel pathogenesis of recurrent meningitis successfully treated by eculizumab. BMJ Case Rep 2018;2018:bcr-2018-225910. [PMID: 30262533 DOI: 10.1136/bcr-2018-225910] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
21 Kinoshita T. Congenital Defects in the Expression of the Glycosylphosphatidylinositol-Anchored Complement Regulatory Proteins CD59 and Decay-Accelerating Factor. Seminars in Hematology 2018;55:136-40. [DOI: 10.1053/j.seminhematol.2018.04.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
22 Tabib A, Hindi I, Karbian N, Zelig O, Falach B, Mevorach D. Prothrombotic mechanisms in patients with congenital p.Cys89Tyr mutation in CD59. Thromb Res 2018;168:67-77. [PMID: 29929138 DOI: 10.1016/j.thromres.2018.06.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
23 Winthrop KL, Mariette X, Silva JT, Benamu E, Calabrese LH, Dumusc A, Smolen JS, Aguado JM, Fernández-Ruiz M. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect 2018;24 Suppl 2:S21-40. [PMID: 29447987 DOI: 10.1016/j.cmi.2018.02.002] [Cited by in Crossref: 121] [Cited by in F6Publishing: 95] [Article Influence: 30.3] [Reference Citation Analysis]
24 Land WG. Humoral Innate Immune Effector Responses. Damage-Associated Molecular Patterns in Human Diseases 2018. [DOI: 10.1007/978-3-319-78655-1_23] [Reference Citation Analysis]
25 Fisher AJ, Cipolla E, Varre A, Gu H, Mickler EA, Vittal R. Potential Mechanisms Underlying TGF-β-mediated Complement Activation in Lung Fibrosis. Cell Mol Med Open Access 2017;3:14. [PMID: 29377033 DOI: 10.21767/2573-5365.100037] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
26 Watad A, Al-Saleh J, Lidar M, Amital H, Shoenfeld Y. Rheumatology in the Middle East in 2017: clinical challenges and research. Arthritis Res Ther 2017;19:149. [PMID: 28666485 DOI: 10.1186/s13075-017-1359-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
27 Tabib A, Karbian N, Mevorach D. Demyelination, strokes, and eculizumab: Lessons from the congenital CD59 gene mutations. Mol Immunol 2017;89:69-72. [PMID: 28622911 DOI: 10.1016/j.molimm.2017.05.024] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
28 Hawksworth OA, Li XX, Coulthard LG, Wolvetang EJ, Woodruff TM. New concepts on the therapeutic control of complement anaphylatoxin receptors. Mol Immunol 2017;89:36-43. [PMID: 28576324 DOI: 10.1016/j.molimm.2017.05.015] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 10.6] [Reference Citation Analysis]
29 Blom AM. The role of complement inhibitors beyond controlling inflammation. J Intern Med 2017;282:116-28. [PMID: 28345259 DOI: 10.1111/joim.12606] [Cited by in Crossref: 41] [Cited by in F6Publishing: 46] [Article Influence: 8.2] [Reference Citation Analysis]